Résumé
La prise en charge des patients atteints de cancer nécessite le développement et la validation de nouveaux outils diagnostiques, pronostiques et/ou prédictifs de la réponse ou de la toxicité des traitements. La métabolomique dresse un portrait dynamique de l’état métabolique d’une tumeur, en réponse à des stimuli physiopathologiques (prolifération ou fonte tumorale), permettant la compréhension des mécanismes moléculaires impliqués. Les premières études publiées présentent des données encourageantes pour la poursuite de l’utilisation de la métabolomique dans la recherche de transfert en cancérologie. L’étude des perturbations du réseau métabolique pourrait permettre en effet d’identifier de nouveaux biomarqueurs et/ou de nouvelles cibles thérapeutiques.
Abstract
Development and validation of novel diagnostic and prognostic tools for cancer patients are a clinically unmet need, especially to help predicting survival or treatment response and toxicity. Metabolomics provides a dynamic portrait of the metabolic state of a tumour in response to pathophysiological stimuli (such as tumour growth or tumour shrinkage) and helps us understand the molecular mechanism sustaining these phenomena. Recent literature presented encouraging data on potential applications of metabolomics in translational research. Analysis of alterations of the metabolic network may lead to identify novel biomarkers and/or therapeutic target.
Références
Bathen TF, Jensen LR, Sitter B, et al. (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104: 181–9
Benyoseph O, Badargoffer RS, Morris PG, et al. (1993) Glycerol 3-phosphate and lactate as indicators of the cerebral cytoplasmic redox state in severe and mild hypxia respectively: a C-13-NMR and P-31-NMR study. Biochem J 291: 915–9
Cairns RA, Papandreou I, Sutphin PD, et al. (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104: 9445–50
Chan EC, Koh PK, Mal M, et al. (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8: 352–61
Cheng LL, Chang IW, Louis DN, et al. (1998) Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 58: 1825–32
Cheng LL, Ma MJ, Becerra L, et al. (1997) Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94: 6408–13
Clayton TA, Lindon JC, Cloarec O, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073–7
Coy JF, Dressler D, Wilde J, et al. (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51: 257–73
Cui Q, Lewis IA, Hegeman AD, et al. (2008) Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol 26: 162–4
Dettmer K, Aronov PA, Hammock BD (2007) Mass spectrometry-based metabolomics. Mass Spectrom Rev 26: 51–78
Dunn WB, Ellis DI (2005) Metabolomics: current analytical platforms and methodologies. TrAC, Trends Anal Chem 24: 285–94
Eisen MB, Spellman PT, Brown PO, et al. (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863–8
El-Deredy W, Ashmore SM, Branston NM, et al. (1997) Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks. Cancer Res 57: 4196–9
Ernst RR, Bodenhausen G, Wokaun A (1987) Principles of nuclear magnetic resonance in one and two dimensions. Clarendon Press, Oxford
Fiehn O, Kopka J, Dormann P, et al. (2000) Metabolite profiling for plant functional genomics. Nat Biotechnol 18: 1157–61
Glunde K, Serkova NJ (2006) Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 7: 1109–23
Griffin JL, Shockcor JP (2004) Metabolic profiles of cancer cells. Nat Rev Cancer 4: 551–61
Holmes E, Loo RL, Stamler J, et al. (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453: 396–400
Howe FA, Barton SJ, Cudlip SA, et al. (2003) Metabolic profiles of human brain tumors using quantitative in vivo H-1 magnetic resonance spectroscopy. Magn Reson Med 49: 223–32
Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13: 472–82
Lindon JC, Holmes E, Nicholson JK (2003) So whats the deal with metabonomics? Metabonomics measures the fingerprint of biochemical perturbations caused by disease, drugs, and toxins. Anal Chem 75: 384A–91A
Lyng H, Sitter B, Bathen TF, et al. (2007) Metabolic mapping by use of highresolution magic angle spinning H-1 MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7: 11
Madsen R, Lundstedt T, Trygg J (2010) Chemometrics in metabolomics: a review in human disease diagnosis. Anal Chim Acta 659: 23–33
Nicholson JK, Lindon JC (2008) Systems biology-metabonomics. Nature 455: 1054–6
Odunsi K, Wollman RM, Ambrosone CB, et al. (2005) Detection of epithelial ovarian cancer using H-1-NMRbased metabonomics. Int J Cancer 113: 782–8
Piotto M, Moussallieh FM, Dillmann B, et al. (2009) Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning H-1 magnetic resonance spectroscopy. Metabolomics 5: 292–301
Powers R (2009) NMR metabolomics and drug discovery. Magn Reson Chem 47: S2–S11
Preul MC, Caramanos Z, Collins DL, et al. (1996) Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 2: 323–5
Robertson DG (2005) Metabonomics in toxicology: a review. Toxicol Sci 85: 809–22
Shulaev V (2006) Metabolomics technology and bioinformatics. Brief Bioinform 7: 128–39
Spratlin JL, Serkova NJ, Eckhardt SG (2009) Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15: 431–40
Sreekumar A, Poisson LM, Rajendiran TM, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910–4
Stahle L, Wold S (1989) Analysis of variance (Anova). Chemometrics Intellig Lab Syst 6: 259–72
Swanson MG, Zektzer AS, Tabatabai ZL, et al. (2006) Quantitative analysis of prostate metabolites using H-1 HR-MAS spectroscopy. Magn Reson Med 55: 1257–64
Tamayo P, Slonim D, Mesirov J, et al. (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 96: 2907–12
Trygg J, Wold S (2002) Orthogonal projections to latent structures (OPLS). J Chemometrics 16: 119–28
Ulrich EL, Akutsu H, Doreleijers JF, et al. (2008) BioMagResBank. Nucleic Acids Res 36: D402–D8
Warburg O (1956) Origin of cancer cells. Science 123: 309–14
Wishart DS (2007) Current progress in computational metabolomics. Brief Bioinform 8: 279–93
Wishart DS, Knox C, Guo AC, et al. (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37: D603–D10
Wold S, Esbensen K, Geladi P (1987) Principal component analysis. Chemometrics Intellig Lab Syst 2: 37–52
Wold S, Sjostrom M, Eriksson L (2001) PLS-regression: a basic tool of chemometrics. Chemometrics Intellig Lab Syst 58: 109–30
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jobard, E., Trédan, O., Elena, B. et al. La métabolomique: un nouvel outil pour la recherche translationnelle en cancérologie. Bio trib. mag. 36, 24–29 (2010). https://doi.org/10.1007/s11834-010-0026-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11834-010-0026-4